D Ioannides, N Antonakopoulos, S Georgiou, V Chasapi, I Katsantonis, A Drosos, D Rigopoulos, C Antoniou, G Anastasiadis, I Bassukas, D Ioannidou, A Protopapa, O Neofotistou, K Krasagakis, P Aronis, M Papageorgiou, E Lazaridou, A Patsatsi, I Lefaki, A V Roussaki-Schulze, F Satra, Z Anagnostopoulos, M Papakonstantis
BACKGROUND: Apremilast is an oral phosphodiesterase-4 inhibitor indicated for patients with moderate-to-severe chronic plaque psoriasis and active psoriatic arthritis. OBJECTIVES: To examine the effectiveness of apremilast on Dermatology Life Quality Index (DLQI), Psoriasis Area and Severity Index (PASI) and nail, scalp and palmoplantar involvement, when administered prior to biologics. METHODS: This 52-week real-world study included biologic-naive adults with moderate psoriasis (psoriasis-involved body surface area 10% to <20%, or PASI 10 to <20 and DLQI 10 to <20)...
September 2021: Journal of the European Academy of Dermatology and Venereology: JEADV